Members' Directory

Biography: Stefan Bonn conducted his undergraduate studies at the German Cancer Research Center (DKFZ) and the University of Bayreuth, working on structural and kinetic aspects of kinase-inhibitor interactions, finishing his diploma thesis in 2004.
Subsequently, he shifted his research interests to genomic and biochemical aspects of learning and memory, working in the Seeburg laboratory at the Max-Planck-Institute for Medical Research in Heidelberg. He obtained his PhD from the University of Heidelberg in 2007.
Pursuing his interest in genomics of development and disease, he then worked as an interdisciplinary postdoctoral fellow (EIPOD) in the Furlong and Gavin groups at the EMBL in Heidelberg, focusing on the regulatory roles of transcription factors and histone modifications during embryogenesis.
Since 2012 Stefan Bonn is an independent research group leader at the German Center for Neurodegenerative Diseases (DZNE) in Goettingen, focusing on the network analysis of neurodegenerative diseases with a special interest in epigenome-environment interactions.
Stefan Bonn has a genuine curiosity in interdisciplinary research and received throughout his career training in bioinformatics (genomics), neuroscience, biochemistry, and genetics.

Biography: Born 1978 in Heidelberg Marc studied Molecular Biology at the Universities of Heidelberg and Manchester, UK (ERASMUS) from 2000 to 2004 and was one of two selected German fellows who graduated in the “International Graduate Programme Molecular & Cellular Biology” of the ZMBH in cooperation with the DKFZ Heidelberg. He gained a broad expertise in biomedical research at the ZMBH, DKFZ, the EMBL and Cellzome. Between 2005 and 2009 he performed his PhD studies on “Functional Proteomics of Bcr-Abl Signaling” at CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna. He discovered a novel leukemia protein complex around the oncogene Bcr-Abl and described its destruction by state-of-the-art leukemia therapeutic agents. Marc is co-author of scientific papers in Cell, Genes & Development, the Proceedings of the National Academy of Sciences of the United States of America and Molecular Systems Biology.
Since November 2009, Marc works on the human chaperone and protein homeostasis networks as drug targets in neurodegenerative diseases as Systems Biologist at Proteostasis Therapeutics Inc. in Cambridge, MA, and as as Research Fellow in the laboratory of Prof. Marc Vidal at the Center for Cancer Systems Biology (CCSB) of the Dana-Farber Cancer Institute in Boston, Massachusetts, and the Department of Genetics at Harvard Medical School.
Marc also combines several years of experience in international science communication, project management and leadership having held various executive positions in pan-European non-governmental biotech organizations such as the Young European Biotech Network (YEBN). In 2006 he co-founded YEBN Ltd., served as its first CEO and represented the network as Executive Board member of the European Federation of Biotechnology (EFB) until 2007. From 2008 - 2011 Marc served on the Advisory Editorial Board of “New Biotechnology”, the official journal of the EFB published by Elsevier.
http://www.marcbrehme.com

Biography: 1992 - 1996 University of Heidelberg, Institut of Neurobiology, Dr. Hans-Herrmann Gerdes Group
1996 - 2000 University of Heidelberg, ZMBH, Group of Prof. Konrad Beyreuther, Alzheimer Research
2001 - 2002 University of Kuopio, Finland, Dr. Carsten Carlbergs Group, Biochemistry
2002 - 2003 EMBL, Heidelberg, Dr. Eileen Furlongs Group, Dev. Biology
- July 2003 Max-Planck Institut, Heidelberg, Dr. Jochen Reinsteins Group, Biochemistry and Biophysics

Biography: I am currently setting-up and maintaining analytical pipelines for analysing NGS data derived from the DNA of tumor biosy and matched peripheral
blood lymphocytes.